Q-omics provides the consensus-scored PARP10 profile across patient tissues and cancer cell-line models. PARP10 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, PARP10 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, PARP10 RNA expression shows 17,254 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, KIRC, and ACC as cancer lineages where PARP10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PARP10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PARP10 survival associations across molecular data types. PARP10 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PARP10 RNA expression–survival associations across cancer types. High PARP10 expression shows unfavorable associations in UVM, LGG, COAD and LAML, but favorable associations in SKCM and MESO. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for PARP10 RNA expression.
This table summarizes PARP10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PARP10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PARP10 shows higher tumor expression in KIRC, COAD, HNSC, BLCA, STAD and LIHC. The KIRC box plot shows higher PARP10 RNA expression in tumor versus normal tissue (log2 FC = +1.306, t-test p < 0.001).
This table shows molecular features associated with PARP10 in patient tissues and cancer cell lines. In patient samples, PARP10 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PARP10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SKIN.
